6978 Stock Overview
A cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Immunotech Biopharm Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.86 |
| 52 Week High | HK$5.00 |
| 52 Week Low | HK$1.50 |
| Beta | 0.89 |
| 11 Month Change | -0.53% |
| 3 Month Change | -37.58% |
| 1 Year Change | -51.94% |
| 33 Year Change | -87.84% |
| 5 Year Change | n/a |
| Change since IPO | -87.98% |
Recent News & Updates
Shareholder Returns
| 6978 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 3.3% | 5.1% | -2.8% |
| 1Y | -51.9% | -13.7% | 10.0% |
Return vs Industry: 6978 underperformed the Hong Kong Biotechs industry which returned -13.7% over the past year.
Return vs Market: 6978 underperformed the Hong Kong Market which returned 10% over the past year.
Price Volatility
| 6978 volatility | |
|---|---|
| 6978 Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 6978 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6978's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 202 | Yu Wang | www.eaal.net |
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer.
Immunotech Biopharm Ltd Fundamentals Summary
| 6978 fundamental statistics | |
|---|---|
| Market cap | HK$957.13m |
| Earnings (TTM) | -HK$332.39m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs 6978 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6978 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥309.22m |
| Earnings | -CN¥309.22m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 364.8% |
How did 6978 perform over the long term?
See historical performance and comparison